ARTIOS PHARMA LTD has a total of 20 patent applications. It increased the IP activity by 600.0%. Its first patent ever was published in 2017. It filed its patents most often in United Kingdom and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ONCOTARTIS INC, GOLDFINCH BIO INC and Inthera Bioscience AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 14 | |
#2 | WIPO (World Intellectual Property Organization) | 6 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Mccarron Hollie | 4 |
#2 | Charles Mark | 4 |
#3 | Ekwuru Tennyson | 4 |
#4 | Blencowe Peter | 4 |
#5 | Heald Robert | 3 |
#6 | Macdonald Ellen | 2 |
#7 | Stockley Martin | 2 |
#8 | Rigoreau Laurent | 2 |
#9 | Finch Harry | 2 |
#10 | Robinson Helen Marie Ruth | 1 |
Publication | Filing date | Title |
---|---|---|
GB202101715D0 | Novel process | |
GB202101573D0 | Novel compounds | |
GB202015545D0 | Novel compounds | |
WO2021028670A1 | Deuterated compounds for use in the treatment of cancer | |
GB201918587D0 | Novel compounds | |
GB201917863D0 | Novel compounds | |
WO2021028643A1 | Heterocyclic compounds for use in the treatment of cancer | |
WO2021028644A1 | Novel therapeutic use | |
WO2020030924A1 | Thiazoleureas as anticancer agents | |
GB201909439D0 | Novel construct | |
GB201821000D0 | Novel compounds | |
GB201817921D0 | Novel compounds | |
GB201813049D0 | Novel Compounds | |
GB201813071D0 | Novel therapeutic use | |
GB201813060D0 | Novel compounds | |
GB201803042D0 | Novel Compounds | |
GB201802117D0 | Novel compounds | |
GB201719720D0 | Novel compounds |